Variant Bio logo

Variant Bio

variantbio.com

Variant Bio develops therapies by studying the genes of people with exceptional health-related traits. It uses insights from human genetics to inform drug discovery and development, aiming to improve global health while prioritizing ethical partnerships and benefit-sharing with participating communities.

Facts

HQ
Seattle
Sectors
Biotechnology Research
Founded
2018
Employees
38
Stage
startup
Members see funding amounts.
.
Founders
Stephane Castel, PhD

Is this your organization? Claim it

Seattle Genomics Startup Variant Bio Secures Up to $50M Deal with Novo Nordisk to Study Metabolic Diseases Using Diverse Genomic Data

Seattle-based Variant Bio has partnered with Novo Nordisk in a multi-year deal worth up to $50 million to study metabolic diseases using genomic data from diverse populations. The collaboration aims to discover novel drug targets for diseases like obesity and diabetes by leveraging genetic data from globally diverse and underrepresented groups.

People

  • Stephane Castel Founder, Chief Technology Officer & Chief Scientific Officer
  • Andrew Farnum Executive, Chief Executive Officer
  • Craig Basson Executive, Chief Medical Officer, President of R&D

Online